**Author details**

Naveen Singh1 , Edward A. Motea1 , Xiumei Huang2 , Colton L. Starcher1 , Jayne Silver1 , I-Ju Yeh1 , S. Louise Pay1 , Xiaolin Su1 , Kristen A. Russ3 , David A. Boothman1† and Erik A. Bey1 \*

1 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

2 Department of Radiation Oncology, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

3 Translational Research Core, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

\*Address all correspondence to: beye@iu.edu

† Deceased

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**151**

*NQO1-Bioactivatable Therapeutics as Radiosensitizers for Cancer Treatment*

activity is the principal determinant of beta-lapachone cytotoxicity. The Journal of Biological Chemistry.

[11] Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calciumdependent modulation of poly(ADPribose) polymerase-1 alters cellular metabolism and DNA repair. The Journal of Biological Chemistry.

2000;**275**:5416-5424

2006;**281**:33684-33696

[12] Boothman DA, Pardee AB. Inhibition of radiation-induced neoplastic transformation by betalapachone. Proceedings of the National Academy of Sciences of the United States of America. 1989;**86**:4963-4967

[13] Boothman DA, Meyers M,

1993;**90**:7200-7204

Cell. 2016;**30**:940-952

Fukunaga N, Lee SW. Isolation of x-rayinducible transcripts from radioresistant human melanoma cells. Proceedings of the National Academy of Sciences of the United States of America.

[14] Huang X, Motea EA, Moore ZR, et al. Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADPribose) polymerase inhibitors. Cancer

[15] Oh ET, Kim JW, Kim JM, et al. NQO1 inhibits proteasome-mediated degradation of HIF-1alpha. Nature Communications. 2016;**7**:13593

[16] Huang X, Dong Y, Bey EA, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1 induced programmed necrosis. Cancer

Swamynathan M, Deschenes A, et al. Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death. Clinical Cancer Research.

Research. 2012;**72**:3038-3047

[17] Froeling FEM, Mosur

2019

*DOI: http://dx.doi.org/10.5772/intechopen.90205*

management. Cancer. 1983;**51**:2506-2514

[2] Lederman M. The early history of radiotherapy: 1895-1939. International Journal of Radiation Oncology, Biology,

Williams MV, Burnet NG. Advances in radiotherapy. BMJ. 2012;**345**:e7765

[4] Durand RE. Roles of thiols in cellular radiosensitivity. International Journal of Radiation Oncology, Biology, Physics.

radiosensitizers for use in radiotherapy. Clinical Oncology (Royal College of Radiologists). 2007;**19**:397-417

[6] Lee MW, Parker WB, Xu B. New insights into the synergism of

nucleoside analogs with radiotherapy. Radiation Oncology. 2013;**8**:223

[7] Revesz L, Palcic B. Radiation dose dependence of the sensitization by oxygen and oxygen mimic sensitizers.

Acta Radiologica. Oncology.

[8] Raleigh DR, Haas-Kogan DA. Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncology.

[9] Boothman DA, Greer S, Pardee AB. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Research. 1987;**47**:5361-5366

[10] Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase

1985;**24**:209-217

2013;**9**:219-233

[1] Brady LW. The changing role of radiation oncology in cancer

Physics. 1981;**7**:639-648

1984;**10**:1235-1238

[5] Wardman P. Chemical

[3] Ahmad SS, Duke S, Jena R,

**References**

*NQO1-Bioactivatable Therapeutics as Radiosensitizers for Cancer Treatment DOI: http://dx.doi.org/10.5772/intechopen.90205*
